

## Coronavirus Statement

Coronavirus (COVID-19) is posing significant challenges for countries around the world, with the situation developing rapidly.

The Polypipe Group leadership team continues to monitor the situation closely and take appropriate actions where necessary. The health, safety and wellbeing of our people has always been, and continues to be, at the forefront of everything we do. The Group and its leadership team has a duty of care to its employees and customers, and the evaluation of risk and taking mitigating actions to protect our employees and customers is taken very seriously and is very much ingrained in our culture.

To that end, the actions we are taking include the following:

- Implementing business continuity plans to mitigate the specific risks associated with Coronavirus, to ensure disruption to normal operations and customer service is minimised.
- Increasing short term stock levels of core product ranges whilst employee numbers allow, to minimise supply disruption to our customers.
- Cancelling all non-essential overseas travel, including to and from our own overseas operations.
- Using electronic means of communication with customers, suppliers and employees where possible, minimising unnecessary social proximity.
- Where meetings may lead to social proximity, the judgement and wishes of the affected employee(s) will be respected by Polypipe without question.
- Instigating a regular internal communications programme to ensure our employees are aware of the latest relevant government advice regarding self-isolating, general WHO health advice, and the support that the Group can provide.
- We have a small manufacturing plant in Genoa, Italy which is continuing to operate under Italian Government guidelines, and we are supporting our small number of overseas employees in the Middle East, Netherlands, France and Ireland as appropriate.
- Setting up a team of senior leaders to monitor and manage the situation as it develops.

There are certain features of the Polypipe Group's business model that give it resilience when faced with situations like this:

- We have 19 sites in the Group, 15 of which are in the UK, 11 of which are manufacturing sites, giving us a degree of flexibility in production, and flexibility of locations for key back office staff.
- We have over 200 injection moulding machines and over 100 extruders, which means we can manage our capacity in small increments and decrements, allowing us to closely match production to demand or available workforce.
- Our primary supply chain has limited dependence on overseas suppliers, and where there is dependence it is generally in areas that do not impact the Group's core product ranges.

We will continue to monitor events and take actions where necessary and will update further as appropriate.



**Martin Payne**  
**Chief Executive Officer**  
**Polypipe Group PLC**